Pricing Log in Create free account
Sunday 11 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

AbbVie Inc. 10-Q filed Aug 3, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 2:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 8, 2026: 18 added · 2 removed · 32 modified; 7 with only figures updated; 8 moved without change

  1. Modified

    The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of March 31June 30, 2026 and December 31, 2025 and the results of operations for the three and six months ended March 31June 30, 2026 and 2025. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”

51 more changes in this Item, word by word, in Powerpack.

Powerpack